The team

Our people are our strength

Executive leadership team

Oriol Casanovas, PhD.
Co-Founder & interim CEO

Dr. Casanovas is an internationally renowned biomedical researcher with extensive knowledge and experience in basic and translational research focused on determining the consequences of adaptation and resistance to therapies against cancer.

Gabriela Jiménez, PhD.
Co-Founder & COO

Dr. Jiménez has a PhD in Biomedicine from the University of Barcelona and studies BSM, EADA business school and IESE. She is experienced in business development, drug development and biomarker discovery.

Bart Huisken, MBA.
Co-Founder & Business and Financial Strategist

Strategic advisor Co-founded 7 businesses
over 20+ years, Business Angel and NED

Advisor team

Itziar Canamasas, PhD.
Business Advisor & Chairwoman

Dr. Canamasas is a highly experienced pharmaceutical executive with a PhD in Tumor Genetics from the University of Mainz and studies at Harvard Business School and IMD Business School.

Luis Correia, DPhil, MBA
Business Strategy

Former Roche executive with 20+ years in partnering, strategy, and investor relations.

Richard Roberts, PhD.
Medicinal Chemistry Advisor

20+ years in drug development


Scott Wilhem
Product Development Strategic Advisor

Former director of oncology discovery at Bayer

Mark Tebbe
Operational and Chemistry Advisor

20+ years in drug development


Todd Snowden
IVD Strategic & Commercial Development Advisor

25+ years in MedTech. IVD expert & biomarker lead

Research team

Our academic founders have played a key role in demonstrating that resistance to cancer therapy occurs in response to adaptive mechanisms of tumor cells.

We are part of the Program Against Cancer Therapeutic Resistance (ProCURE)

We research resistance mechanisms and tumor malignization

We are always looking for new talent to join our team